Day 2 | Patient Group Reflections on the Case for CGP Investment | #BIOMARKERS26

As health systems across Canada consider integrating CGP into standard cancer care, patient groups play a critical role in highlighting access gaps and articulating priorities for investment. This roundtable brings together patient organizations from across tumour types to reflect on advocating for CGP, including early insights from CCRAN's CGP Phase II Research Initiative. Topics discussed: • The role of real-world evidence in informing CGP implementation • How patient groups engage stakeholders to shape priorities and inform decision-making • Barriers to achieving consistent access and standardization of CGP testing across jurisdictions • Strategic approaches to strengthen advocacy impact across jurisdictions Moderator: Filomena Servidio-Italiano — President & CEO, CCRAN Patient Group Roundtable: Ayelet Borgida (Pancreatic Cancer North America), Lindsay Timm (CCSN), Winky Yau (Lung Cancer Canada), Teresa Norris (HPV Global Action), JK Miller (Canadian Breast Cancer Network), Laz Bouros (Thyroid Foundation of Canada), Austin Zimmer (Prostate Cancer Foundation Canada), Shannon Phillips (My Gut Feeling – Stomach Cancer Foundation of Canada) This session was recorded during CCRAN's 2026 Biomarkers Conference (June 18–19, 2026), a national event bringing together clinicians, researchers, policy professionals, patients, and caregivers to advance a coordinated strategy for comprehensive genomic profiling in Canada. Learn more about CCRAN: https://ccran.org Explore more Biomarkers Conference sessions:    • 2026 Biomarkers Conference | #BIOMARKERS26